News & Updates

Show Multimedia Only

Ixekizumab plus tirzepatide confers multiple benefits in patients with psoriasis, high BMI

27 May 2026 by

Taking ixekizumab and tirzepatide together results in higher rates of skin clearance and weight loss compared with ixekizumab alone in patients with psoriasis and overweight or obesity, who represent a population that is difficult to treat, according to the phase IIIb TOGETHER-PsO trial.

Ixekizumab plus tirzepatide confers multiple benefits in patients with psoriasis, high BMI

27 May 2026

Novel small-molecule TLR7/8 inhibitor shows therapeutic potential in lupus

20 May 2026

The oral small-molecule TLR7/8 inhibitor enpatoran has shown a dose-dependent effect on disease activity in patients with active skin manifestations of cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) in the phase II WILLOW trial.

Novel small-molecule TLR7/8 inhibitor shows therapeutic potential in lupus

20 May 2026

Lower socioeconomic status tied to poorer RA outcomes

19 May 2026 by

Patients with rheumatoid arthritis (RA) who are living in areas with disadvantageous socioeconomic status (SES) appear to have higher disease activity, disability, and poorer quality of life (QOL), as shown in a study in Australia.

Lower socioeconomic status tied to poorer RA outcomes

19 May 2026

Discrimination tied to poor patient outcomes in SLE

19 May 2026

Racial and ethnic discriminations appear to result in greater patient-reported disease activity, pain, fatigue, depression, and anxiety among patients with systemic lupus erythematosus (SLE), a recent study has shown.

Discrimination tied to poor patient outcomes in SLE

19 May 2026

$RA tied to poor survival after fracture$

RA tied to poor survival after fracture

18 May 2026

Individuals with rheumatoid arthritis (RA) appear to be at increased risk of death following a fracture, reveals a study, noting that post-fracture survival has not improved despite therapeutic advances over the past decades.

RA tied to poor survival after fracture

18 May 2026

Vunakizumab beneficial in axial spondyloarthritis

16 May 2026

Treatment with vunakizumab appears to yield substantial improvements in signs and symptoms of radiographic axial spondyloarthritis (r-axSpA), as shown in a phase 2/3 trial.

Vunakizumab beneficial in axial spondyloarthritis

16 May 2026

Original New Drug Application Approvals by US FDA (16-30 April 2026)

11 May 2026

New drug applications approved by US FDA as of 16-30 April 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 April 2026)

11 May 2026

Branebrutinib makes no difference in RA management

07 May 2026

A phase 2a trial of rheumatoid arthritis (RA) has shown no significant difference between the investigational branebrutinib and placebo in terms of clinical efficacy, despite the drug having a favourable safety profile.

Branebrutinib makes no difference in RA management

07 May 2026

IPF tied to lower survival than SARD-ILD

29 Apr 2026

Patients with systemic autoimmune rheumatic disease (SARD)-associated interstitial lung disease (ILD) tend to live longer than those with idiopathic pulmonary fibrosis (IPF), reveals a study.

IPF tied to lower survival than SARD-ILD

29 Apr 2026

Original New Drug Application Approvals by US FDA (16-31 March 2026)

29 Apr 2026

New drug applications approved by US FDA as of 16-31 March 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 March 2026)

29 Apr 2026

News & Updates

Showing Rheumatology articles

Showing

Specialty:

Ixekizumab plus tirzepatide confers multiple benefits in patients with psoriasis, high BMI

Ixekizumab plus tirzepatide confers multiple benefits in patients with psoriasis, high BMI

Novel small-molecule TLR7/8 inhibitor shows therapeutic potential in lupus

Novel small-molecule TLR7/8 inhibitor shows therapeutic potential in lupus

Lower socioeconomic status tied to poorer RA outcomes

Lower socioeconomic status tied to poorer RA outcomes

Discrimination tied to poor patient outcomes in SLE

Discrimination tied to poor patient outcomes in SLE

RA tied to poor survival after fracture

RA tied to poor survival after fracture

Vunakizumab beneficial in axial spondyloarthritis

Vunakizumab beneficial in axial spondyloarthritis

Original New Drug Application Approvals by US FDA (16-30 April 2026)

Original New Drug Application Approvals by US FDA (16-30 April 2026)

Branebrutinib makes no difference in RA management

Branebrutinib makes no difference in RA management

IPF tied to lower survival than SARD-ILD

IPF tied to lower survival than SARD-ILD

Original New Drug Application Approvals by US FDA (16-31 March 2026)

Original New Drug Application Approvals by US FDA (16-31 March 2026)